An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy
Authors' conclusion
This study discovered a 22-metabolite panel to discriminate patients with csPCa from Be + ciPCa patients when combined with age, PSA, and %fPSA. It may therefore be used as a supportive biomarker to reduce the number of unnecessary biopsies and also to identify novel therapeutic targets in the future.
Study context
- Population
- Patients undergoing prostate biopsy with clinical suspicion of prostate cancer (PCa): csPCa (ISUP 2–5), ciPCa (ISUP 1), benign (negative biopsy)
- Participants
- 1,078 serum samples
- Comparison
- 22-metabolite panel plus clinical parameters vs clinical parameters alone for csPCa vs ciPCa + benign
- Outcome
- Discrimination of csPCa from Be + ciPCa
Methodological detailsNuclear magnetic resonance (NMR) spectroscopy, random forest model
- NMR spectroscopy
- Random forest model
Performance
As reported in the abstract
| Test or model | AUC |
|---|---|
| Panel + clinical parameters | 0.84 |
| Clinical parameters | 0.73 |
AUC
Panel + clinical parameters0.84
Clinical parameters0.73
Further findings
| Outcome | P value |
|---|---|
| Serum ornithine and dimethylglycine, csPCa vs Be + ciPCaHigher ornithine and lower dimethylglycine in csPCa | P < 0.001 |
- Serum ornithine and dimethylglycine, csPCa vs benign (Be) + ciPCa — Ornithine, csPCa vs Be + ciPCa
- 63.7 ± 26.5 vs 50.3 ± 31.6 µmol/L
- Serum ornithine and dimethylglycine, csPCa vs Be + ciPCa — Dimethylglycine, csPCa vs Be + ciPCa
- 12.6 ± 6.3 vs 14.9 ± 7.7 µmol/L
- Serum ornithine and dimethylglycine, csPCa vs Be + ciPCa: ornithine and dimethylglycine were the 2 most important features
Metabolic pathways in csPCa
- Significant dysregulation of urea cycle and choline pathway, changes in TCA cycle and cholesterol metabolism, significant increase of glycoprotein acetyls B in csPCa
Original publication
An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy. J Clin Endocrinol Metab. Published 9 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →